A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma
Pemigatinib, a pan-FGFR inhibitor, is approved to treat intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusion mutations. Improving its targeting of FGFR2 fusions remains an unmet clinical need due to its pan selectivity and resistance. Here, we report a cholesterol-conjugated DNA/RNA heterodu...
Main Authors: | Zhenzhen Chu, Baohuan Zhang, Xuxuan Zhou, Hui Yuan, Chongqing Gao, Lihao Liu, Yang Xiao, Jichun Zhang, Jian Hong, Junjie Liang, Dong Chen, Nan Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253123002652 |
Similar Items
-
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01) -
The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
by: Salati M, et al.
Published: (2021-10-01) -
Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
by: Samantha M. Ruff, et al.
Published: (2024-01-01) -
Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
by: Xiaohong Pu, et al.
Published: (2023-11-01) -
A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
by: Lei Zhang, et al.
Published: (2023-06-01)